Iron toxicity studies of quelamycin

Area of Science:

• Pharmacology
• Oncology
• Toxicology

Background:

• Previous phase I quelamycin (NSC-267703) studies showed high rates of generalized toxicity (95%) and cardiotoxicity (38%).
• A modified dosing schedule was proposed to mitigate acute toxicities associated with quelamycin treatment.

Purpose of the Study:

• To evaluate the safety and toxicity profile of a modified intermittent quelamycin dosing schedule.
• To assess the incidence of acute and chronic toxicities, including cardiotoxicity and iron overload, with the new regimen.

Main Methods:

• Quelamycin was administered intravenously at 40 mg/m2 on either 2 or 3 consecutive days.
• Patients receiving multiple courses were monitored for clinical and pathological signs of toxicity.
• Cardiotoxicity and generalized symptoms were assessed in patients on the modified schedule.

Main Results:

• The 2- or 3-day quelamycin course significantly reduced generalized toxicity (55% incidence) and eliminated cardiotoxicity (0% incidence).
• Multiple courses of quelamycin were associated with clinical and pathological findings consistent with early hemochromatosis.
• Acute iron toxicity was successfully prevented with the 3-day administration schedule.

Conclusions:

• A 3-day intermittent quelamycin schedule effectively prevents acute iron toxicity and cardiotoxicity.
• Chronic quelamycin administration may lead to unexpected iron overload toxicity (hemochromatosis).
• Further research is necessary to understand and manage hemochromatosis before broader clinical studies of quelamycin can proceed.